About Kim Blackwell
Kim Blackwell is a director at FORE US Bio.
Kim Blackwell first appears on SEC filings in 2023.
Experience
This experience comes from Kim Blackwell's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kim Blackwell in the role, so the role may have started earlier or lasted longer.
NR
Nucleus RadioPharma Current
Chief Development Officer
2025 – Present
SK
Susan G. Komen Current
Member Board of Directors
2024 – Present
FORE US Bio Inc. Current
Member Board Of Directors
2021 – Present · Philadelphia, PA
Develops targeted cancer drugs for patients whose tumors have specific genetic changes.
CI
Century Therapeutics, Inc Current
Member Board Of Directors
2021 – Present
MT
Monte Rosa Therapeutics Current
Member Board Of Directors
2020 – Present
ZP
Zentalis Pharmaceuticals
Chief Executive Officer
2022 – 2024
TI
Tempus Labs, Inc.
Chief Medical Advisor
2020 – 2023
EC
Eli Lilly and Company
Vice President
2018 – 2020
DC
Duke University Medical Center
Professor
1994 – 2018
Key Colleagues at Startups
The people Kim Blackwell works with at each company, as listed on that company's latest Form D.
FORE US Bio Inc. · Form D/A, Jul 14, 2026
William Hinshaw
Executive officer and director
Michael Byrnes
Chief Financial Officer
Giovanni Mariggi
Co-founder and Partner at Medicxi, director
Erez Chimovits
Senior Managing Director at Orbimed
RD
Rajeev Dadoo
COO and Managing Partner of SR One, director
Dieter Weinand
Chairman of the Board
Chandra Leo
Partner at HBM Partners and director